Key facts, as of
As of October 9, 2026, Thermo Fisher Scientific (TMO) trades at $651.98, up 21.6% over the past year. Its 52-week range runs from $435.27 to $694.33; the price is 6.1% below that high. It is 6.1% below its all-time high of $694.33, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +336.6%, against +312.9% for the S&P 500 (SPY). It sits 19.7% above its 200-day average of $544.53, the usual sign of a long-term uptrend. Its 30-day volatility is 27.4% annualized, which we rate medium risk. It has a trailing P/E of 35.1 and a dividend yield of 0.29%.
Cite: Portfolio Terminal, "Thermo Fisher Scientific (TMO) stock analysis", 2026-10-09. https://portfolio-terminal.com/analyse/tmo
Where it trades today
trading 84% of the way up its 52-week range
How the price has moved
How far it is from its record
Thermo Fisher Scientific (TMO) is 6.1% below its all-time high of $694.33, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +336.6%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- TMO trades at 35.1x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 27.4%, above the sector norm of 22.0%, so position sizing matters more than usual.
- TMO is in a bullish short-term regime and only 6.1% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- TMO is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in TMO.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for TMO come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for TMO. Last refresh: Oct 9, 2026, 10:18 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Thermo Fisher Scientific does
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government,…
Employees
125,000
Industry
Diagnostics & Research
Headquarters
Waltham, United States
What analysts expect
TMO carries a strong buy consensus from 25 analysts, with an average price target of $673.44 versus $651.98 today (+3.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
TMO generated $46.34B in trailing revenue (10.5% year over year), with a 15.0% net margin, and $6.24B of free cash flow, against $38.48B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $44.56B | $18.24B | $8.11B | $6.70B | $17.77 | $6.29B |
| 2024 | $42.88B | $17.70B | $7.72B | $6.33B | $16.58 | $7.27B |
| 2023 | $42.86B | $17.10B | $7.32B | $6.00B | $15.52 | $6.93B |
| 2022 | $44.91B | $18.97B | $8.51B | $6.95B | $17.75 | $6.91B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
TMO is in 7 of the 30 ETFs we track. It weighs most in XLV: 4.06% of the fund, holding #6 of 62.
Famous investors who hold it
TMO is in the latest 13F of 1 of the 15 famous investors we follow. Stanley Druckenmiller (Duquesne Family Office) holds the most of it: 0.18% of the portfolio, position #76 of 94, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
TMO beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, 6.1% under its 1-year high with no resistance above.
uptrend- Price is 4.4% above its 50-day average and 19.7% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-18 (a “golden cross”).
- RSI at 52 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $645.49 (-1.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is TMO a good investment in 2026?
Thermo Fisher Scientific trades at a P/E ratio of 35.1, with medium volatility (27.4% annualized). Recent momentum is positive.
What is the risk level of TMO?
Based on 30-day volatility of 27.4%, TMO has MEDIUM risk. Beta of 0.88 indicates lower sensitivity to market movements than average.
Does TMO pay dividends?
Yes, Thermo Fisher Scientific has a dividend yield of 0.29%.
How far is TMO from its all-time high?
Thermo Fisher Scientific is 6.1% below its all-time high of $694.33, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +336.6%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold TMO?
7 of the 30 popular ETFs we track hold Thermo Fisher Scientific. The largest weights: XLV (4.06%), VTV (0.83%), SPY (0.38%), IVV (0.38%) and VOO (0.35%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is TMO?
0.35%, as of August 31, 2026: TMO is holding #49 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $3.46 in Thermo Fisher Scientific.
Which famous investors own TMO?
Stanley Druckenmiller (0.18% of Duquesne Family Office's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for TMO?
The average analyst price target for Thermo Fisher Scientific (TMO) is $673.44 based on 25 analyst estimates, about 3.3% above the current price of $651.98. The published range runs from $560.00 to $800.00.
How much revenue does TMO generate?
Thermo Fisher Scientific reported $46.34B in trailing twelve-month revenue. Revenue growth is running at 10.5% year over year. Net margin sits at 15.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare TMO with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.